Evidence map›Paper›PMID 41194599›Full record

Trial reportHuman vaccines & immunotherapeutics2025

Immune persistence and safety of the AS01

Murdo Ferguson, Tino F Schwarz, Sebastián A Núñez, Juan Rodríguez-García, Marek Mital, Carlos Zala, Bonavuth Pek, Bernhard Schmitt, Nicole Toursarkissian, Dolores Ochoa Mazarro and 11 more

Abstract readRandomized Controlled TrialClinical Trial, Phase IIIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. AS01Drug safety · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Murdo FergusonColchester Research Group, Truro, Canada.
Tino F SchwarzInstitute of Laboratory Medicine and Vaccination Centre, Klinikum Würzburg Mitte, Campus Juliusspital, Würzburg, Germany.
Sebastián A NúñezCentro Medico Maffei, Buenos Aires, Argentina.
Juan Rodríguez-GarcíaPreventive Medicine Department, Immunocompromised Patient Immunization Unit, Son Espases University Hospital, University of the Balearic Islands (UIB), Balearic Islands Health Research Institute (IdISBa), Palma de Mallorca, Mallorca, Balearic Islands, Spain.
Marek MitalAgnieszka Mital Centrum Badan Klinic, Elblag, Poland.
Carlos ZalaVacunar Sede Las Cañitas, Buenos Aires, Argentina.
Bonavuth PekClinique de Pneumologie et du Sommeil de Lanaudière, Saint-Charles-Borromée, Québec, Canada.
Bernhard SchmittStudienzentrum Mainz Mitte, Mainz, Germany.
Nicole ToursarkissianPraxis Dr. Med. Nicole Toursarkissian, Berlin, Germany.
Dolores Ochoa MazarroClinical Pharmacology Department, Hospital Universitario De La Princesa, Instituto de Investigación Sanitaria La Princesa, Universidad Autónoma de Madrid, Madrid, Spain.
Josef GroßkopfPraxis Dr. Med. Josef Großkopf, Wallerfing, Germany.
Christine Voors-PetteQPS Netherlands B.V, Groningen, The Netherlands.
Hemalini MehtaClinical Research Institute, Minneapolis, MN, USA.
Hiwot Amare HailemariamGSK, Wavre, Belgium.
Catherine GérardGSK, Rixensart, Belgium.
Silvia DamasoGSK, Wavre, Belgium.
Marie-Pierre DavidGSK, Wavre, Belgium.
Dominique DescampsGSK, Wavre, Belgium.
Judith HillGSK, Wavre, Belgium.
Corinne VandermeulenGSK, Wavre, Belgium.
Veronica HulstrømGSK, Wavre, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this phase 3, randomized, placebo-controlled multi-country study, the AS01

Indexed as

Adjuvants, ImmunologicAdjuvants, VaccineRespiratory Syncytial Virus, HumanRespiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesViral Fusion ProteinsAgedAntibodies, NeutralizingAntibodies, ViralDouble-Blind MethodFemaleHumansImmunity, CellularImmunity, HumoralImmunogenicity, VaccineMaleAdjuvants, ImmunologicAdjuvants, VaccineAntibodies, NeutralizingAntibodies, ViralF protein, human respiratory syncytial virusRespiratory Syncytial Virus VaccinesViral Fusion Proteinschronic conditionshumoral and cell-mediated immunityRespiratory syncytial virussafetyvaccination

Identifiers

PMID41194599
PMCPMC12599337

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.